| David I Groman, MD | |
|
99 Beauvoir Ave, Summit, NJ 07901-3533 | |
| (908) 522-2021 | |
| Not Available |
| Full Name | David I Groman |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 21 Years |
| Location | 99 Beauvoir Ave, Summit, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790717890 | NPI | - | NPPES |
| 31756701 | Medicaid | NM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MD2006-0076 (New Mexico) | Secondary |
| 207P00000X | Emergency Medicine | 25MA09225500 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Joseph's Hospital And Medical Center | Paterson, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Passaic River Physicians Llc | 4486041514 | 52 |
News Archive
Epilepsy Therapy Project, a non-profit organization whose mission is to accelerate new therapies for people living with epilepsy and seizures, and ICVrx, LLC, a pharmacy product research and development company focused on novel therapies for central nervous system disorders, announced today that ETP has made an investment in ICVrx to support the development of ICVrx's targeted epilepsy drug technology for patients whose seizures are not controlled by current therapies.
Data from nine cities in Mexico confirms that identifying dengue fever "hot spots" can provide a predictive map for future outbreaks of Zika and chikungunya. All three of these viral diseases are spread by the Aedes aegypti mosquito.
Juventas Therapeutics, a privately held, clinical-stage regenerative medicine company announced it has started enrolling patients in a Phase I clinical trial for JVS-100 to evaluate safety and efficacy in the treatment of patients with Class III heart failure. JVS-100 encodes Stromal Cell-derived Factor-1 (SDF-1) and has been shown in pre-clinical studies to significantly increase cardiac function by promoting cell survival and increasing new blood vessel formation in the damaged organ.
With the flu and cold season in full swing, kinesiology professor Karin Richards, at University of the Sciences in Philadelphia, said many people tend to ignore their symptoms to keep on track with their fitness resolutions for the New Year.
› Verified 8 days ago
| Entity Name | Middlesex Emergency Physicians, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811921760 PECOS PAC ID: 9931002854 Enrollment ID: O20040129000034 |
News Archive
Epilepsy Therapy Project, a non-profit organization whose mission is to accelerate new therapies for people living with epilepsy and seizures, and ICVrx, LLC, a pharmacy product research and development company focused on novel therapies for central nervous system disorders, announced today that ETP has made an investment in ICVrx to support the development of ICVrx's targeted epilepsy drug technology for patients whose seizures are not controlled by current therapies.
Data from nine cities in Mexico confirms that identifying dengue fever "hot spots" can provide a predictive map for future outbreaks of Zika and chikungunya. All three of these viral diseases are spread by the Aedes aegypti mosquito.
Juventas Therapeutics, a privately held, clinical-stage regenerative medicine company announced it has started enrolling patients in a Phase I clinical trial for JVS-100 to evaluate safety and efficacy in the treatment of patients with Class III heart failure. JVS-100 encodes Stromal Cell-derived Factor-1 (SDF-1) and has been shown in pre-clinical studies to significantly increase cardiac function by promoting cell survival and increasing new blood vessel formation in the damaged organ.
With the flu and cold season in full swing, kinesiology professor Karin Richards, at University of the Sciences in Philadelphia, said many people tend to ignore their symptoms to keep on track with their fitness resolutions for the New Year.
› Verified 8 days ago
| Entity Name | Plainfield Emergency Physicians, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659309680 PECOS PAC ID: 7719972728 Enrollment ID: O20040419001065 |
News Archive
Epilepsy Therapy Project, a non-profit organization whose mission is to accelerate new therapies for people living with epilepsy and seizures, and ICVrx, LLC, a pharmacy product research and development company focused on novel therapies for central nervous system disorders, announced today that ETP has made an investment in ICVrx to support the development of ICVrx's targeted epilepsy drug technology for patients whose seizures are not controlled by current therapies.
Data from nine cities in Mexico confirms that identifying dengue fever "hot spots" can provide a predictive map for future outbreaks of Zika and chikungunya. All three of these viral diseases are spread by the Aedes aegypti mosquito.
Juventas Therapeutics, a privately held, clinical-stage regenerative medicine company announced it has started enrolling patients in a Phase I clinical trial for JVS-100 to evaluate safety and efficacy in the treatment of patients with Class III heart failure. JVS-100 encodes Stromal Cell-derived Factor-1 (SDF-1) and has been shown in pre-clinical studies to significantly increase cardiac function by promoting cell survival and increasing new blood vessel formation in the damaged organ.
With the flu and cold season in full swing, kinesiology professor Karin Richards, at University of the Sciences in Philadelphia, said many people tend to ignore their symptoms to keep on track with their fitness resolutions for the New Year.
› Verified 8 days ago
| Entity Name | Emergency Physician Associates Of North Jersey P C |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497783419 PECOS PAC ID: 7911992326 Enrollment ID: O20040825001558 |
News Archive
Epilepsy Therapy Project, a non-profit organization whose mission is to accelerate new therapies for people living with epilepsy and seizures, and ICVrx, LLC, a pharmacy product research and development company focused on novel therapies for central nervous system disorders, announced today that ETP has made an investment in ICVrx to support the development of ICVrx's targeted epilepsy drug technology for patients whose seizures are not controlled by current therapies.
Data from nine cities in Mexico confirms that identifying dengue fever "hot spots" can provide a predictive map for future outbreaks of Zika and chikungunya. All three of these viral diseases are spread by the Aedes aegypti mosquito.
Juventas Therapeutics, a privately held, clinical-stage regenerative medicine company announced it has started enrolling patients in a Phase I clinical trial for JVS-100 to evaluate safety and efficacy in the treatment of patients with Class III heart failure. JVS-100 encodes Stromal Cell-derived Factor-1 (SDF-1) and has been shown in pre-clinical studies to significantly increase cardiac function by promoting cell survival and increasing new blood vessel formation in the damaged organ.
With the flu and cold season in full swing, kinesiology professor Karin Richards, at University of the Sciences in Philadelphia, said many people tend to ignore their symptoms to keep on track with their fitness resolutions for the New Year.
› Verified 8 days ago
| Entity Name | Passaic River Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962162644 PECOS PAC ID: 4486041514 Enrollment ID: O20220420000861 |
News Archive
Epilepsy Therapy Project, a non-profit organization whose mission is to accelerate new therapies for people living with epilepsy and seizures, and ICVrx, LLC, a pharmacy product research and development company focused on novel therapies for central nervous system disorders, announced today that ETP has made an investment in ICVrx to support the development of ICVrx's targeted epilepsy drug technology for patients whose seizures are not controlled by current therapies.
Data from nine cities in Mexico confirms that identifying dengue fever "hot spots" can provide a predictive map for future outbreaks of Zika and chikungunya. All three of these viral diseases are spread by the Aedes aegypti mosquito.
Juventas Therapeutics, a privately held, clinical-stage regenerative medicine company announced it has started enrolling patients in a Phase I clinical trial for JVS-100 to evaluate safety and efficacy in the treatment of patients with Class III heart failure. JVS-100 encodes Stromal Cell-derived Factor-1 (SDF-1) and has been shown in pre-clinical studies to significantly increase cardiac function by promoting cell survival and increasing new blood vessel formation in the damaged organ.
With the flu and cold season in full swing, kinesiology professor Karin Richards, at University of the Sciences in Philadelphia, said many people tend to ignore their symptoms to keep on track with their fitness resolutions for the New Year.
› Verified 8 days ago
| Entity Name | Passaic River Observation, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568113348 PECOS PAC ID: 0143617126 Enrollment ID: O20220421000141 |
News Archive
Epilepsy Therapy Project, a non-profit organization whose mission is to accelerate new therapies for people living with epilepsy and seizures, and ICVrx, LLC, a pharmacy product research and development company focused on novel therapies for central nervous system disorders, announced today that ETP has made an investment in ICVrx to support the development of ICVrx's targeted epilepsy drug technology for patients whose seizures are not controlled by current therapies.
Data from nine cities in Mexico confirms that identifying dengue fever "hot spots" can provide a predictive map for future outbreaks of Zika and chikungunya. All three of these viral diseases are spread by the Aedes aegypti mosquito.
Juventas Therapeutics, a privately held, clinical-stage regenerative medicine company announced it has started enrolling patients in a Phase I clinical trial for JVS-100 to evaluate safety and efficacy in the treatment of patients with Class III heart failure. JVS-100 encodes Stromal Cell-derived Factor-1 (SDF-1) and has been shown in pre-clinical studies to significantly increase cardiac function by promoting cell survival and increasing new blood vessel formation in the damaged organ.
With the flu and cold season in full swing, kinesiology professor Karin Richards, at University of the Sciences in Philadelphia, said many people tend to ignore their symptoms to keep on track with their fitness resolutions for the New Year.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David I Groman, MD 10 Michael Rd, Mendham, NJ 07945-2400 Ph: (313) 549-8698 | David I Groman, MD 99 Beauvoir Ave, Summit, NJ 07901-3533 Ph: (908) 522-2021 |
News Archive
Epilepsy Therapy Project, a non-profit organization whose mission is to accelerate new therapies for people living with epilepsy and seizures, and ICVrx, LLC, a pharmacy product research and development company focused on novel therapies for central nervous system disorders, announced today that ETP has made an investment in ICVrx to support the development of ICVrx's targeted epilepsy drug technology for patients whose seizures are not controlled by current therapies.
Data from nine cities in Mexico confirms that identifying dengue fever "hot spots" can provide a predictive map for future outbreaks of Zika and chikungunya. All three of these viral diseases are spread by the Aedes aegypti mosquito.
Juventas Therapeutics, a privately held, clinical-stage regenerative medicine company announced it has started enrolling patients in a Phase I clinical trial for JVS-100 to evaluate safety and efficacy in the treatment of patients with Class III heart failure. JVS-100 encodes Stromal Cell-derived Factor-1 (SDF-1) and has been shown in pre-clinical studies to significantly increase cardiac function by promoting cell survival and increasing new blood vessel formation in the damaged organ.
With the flu and cold season in full swing, kinesiology professor Karin Richards, at University of the Sciences in Philadelphia, said many people tend to ignore their symptoms to keep on track with their fitness resolutions for the New Year.
› Verified 8 days ago
Anita J Singh, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 99 Beauvoir Ave, Summit, NJ 07901 Phone: 856-686-4306 | |
Kirsten Green, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 99 Beauvoir Ave, Summit, NJ 07901 Phone: 908-522-2232 | |
Christopher Amalfitano, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 99 Beauvoir Ave, Summit, NJ 07901 Phone: 908-522-2232 Fax: 908-522-2274 | |
Dr. Evan Michael Gleimer, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 99 Beauvoir Ave, Summit, NJ 07901 Phone: 908-522-2000 | |
Stephen R. Sabo, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 99 Beauvoir Ave, Summit, NJ 07901 Phone: 908-522-2232 Fax: 908-522-0227 | |
Dr. Zachary Kris Hernandez, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 99 Beauvoir Ave, Summit, NJ 07901 Phone: 908-522-2000 | |
Ruth A. Campo, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 99 Beauvoir Ave, Summit, NJ 07901 Phone: 908-522-2332 Fax: 908-522-0227 |